Catalog No.
KVV00305
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for SARS-CoV-2 RBD (KP.2) has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any SARS-CoV-2 RBD (KP.2) present is bound by the immobilized antibody. After washing away any unbound substances, a biotin-labeled antibody specific for SARS-CoV-2 RBD (KP.2) is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of SARS-CoV-2 RBD (KP.2) bound in the initial step. The color development is stopped and the intensity of the color is measured.
Specificity
SARS-CoV-2 RBD (KP.2)
Applications
Used for the quantitative determination of SARS-CoV-2 RBD (KP.2) concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
23.44 - 1,500 pg/mL
Sensitivity
20.11 pg/mL
Precision
Intra-Assay Precision (Precision within an assay): <10%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <15%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (pg/mL)
|
696.9
|
163.3
|
38.7
|
697.0
|
170.1
|
37.0
|
|
Standard deviation
|
25.1
|
3.7
|
2.3
|
26.6
|
9.1
|
4.5
|
|
CV (%)
|
3.6
|
2.3
|
5.9
|
3.8
|
5.3
|
12.2
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia., PMID:39817585
Anti-SARS-CoV-2 total immunoglobulin and neutralising antibody responses in healthy blood donors throughout the COVID-19 pandemic: a longitudinal observational study., PMID:39137369
Snapshot of Anti-SARS-CoV-2 IgG Antibodies in COVID-19 Recovered Patients in Guinea., PMID:38792506
Efficient transplacental transfer of SARS-CoV-2 antibodies between naturally exposed mothers and infants in Accra, Ghana., PMID:38730052
Microfluidic particle counter visualizing mucosal antibodies against SARS-CoV-2 in the upper respiratory tract for rapid evaluation of immune protection., PMID:38660972
Performance of plant-produced RBDs as SARS-CoV-2 diagnostic reagents: a tale of two plant platforms., PMID:38239207
Characterization of SARS-CoV-2-specific humoral immunity and associated factors in the healthy population post-vaccination., PMID:38103966
Increasing Levels of Serum Anti-Spike S1-RBD IgG after 120 Days of the Pfizer-BioNTech-mRNA Second Dose Vaccination., PMID:38028836
Development of ELISA-Based Assay for Detection of SARS-CoV-2 Neutralizing Antibody., PMID:37643285
Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study., PMID:37437051
Designing and developing a sensitive and specific SARS-CoV-2 RBD IgG detection kit for identifying positive human samples., PMID:36871661
Evaluation of a biotin-based surrogate virus neutralization test for detecting postvaccination antibodies against SARS-CoV-2 variants in sera., PMID:36696754
Development of in House ELISAs to Detect Antibodies to SARS-CoV-2 in Infected and Vaccinated Humans by Using Recombinant S, S1 and RBD Proteins., PMID:36553092
A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity., PMID:36532082
Development and Evaluation of a Rapid Neutralizing Antibody Assay for COVID-19 Vaccination., PMID:36278077
A Versatile Biomimic Nanotemplating Fluidic Assay for Multiplex Quantitative Monitoring of Viral Respiratory Infections and Immune Responses in Saliva and Blood., PMID:36253095
Cohort-Specific Serological Recognition of SARS-CoV-2 Variant RBD Antigens., PMID:36197765
SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays., PMID:36146844
Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals., PMID:36124500
Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial., PMID:36029105
Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2 N and S proteins: mass screening., PMID:35976427
Efficacy of Sinopharm® COVID-19 Vaccine in Hemodialysis Patients: A Preliminary Report., PMID:35962641
High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium., PMID:35746728
Evaluation of Performance of Detection of Immunoglobulin G and Immunoglobulin M Antibody Against Spike Protein of SARS-CoV-2 by a Rapid Kit in a Real-Life Hospital Setting., PMID:35558113
Assessment of specific human antibodies against SARS-CoV-2 receptor binding domain by rapid in-house ELISA., PMID:35431235
Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study., PMID:35378574
Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant., PMID:35198159
Estimating SARS-CoV-2 Seroprevalence in Canadian Blood Donors, April 2020 to March 2021: Improving Accuracy with Multiple Assays., PMID:35196819
Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies., PMID:35187003
Timeline of SARS-CoV-2 Spread in Italy: Results from an Independent Serological Retesting., PMID:35062265
Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody., PMID:34942543
Development and validation of novel kit for quantification of SARS-CoV-2 antibodies on clinical samples., PMID:34919976
Two novel SARS-CoV-2 surrogate virus neutralization assays are suitable for assessing successful immunization with mRNA-1273., PMID:34563583
Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay., PMID:34136587
Robust and low-cost ELISA based on IgG-Fc tagged recombinant proteins to screen for anti-SARS-CoV-2 antibodies., PMID:34051226
COVID-19 in Russia: Clinical and Immunological Features of the First-Wave Patients., PMID:33959390
Application of newly developed SARS-CoV2 serology test along with real-time PCR for early detection in health care workers and on-time plasma donation., PMID:33869895
For research use only. Not for human or drug use.
